IXICO plc Investor Meet Company presentation
May 16 2023 - 2:00AM
RNS Non-Regulatory
TIDMIXI
IXICO plc
16 May 2023
16 May 2023
IXICO plc
("IXICO" or the "Company")
Half-year results investor presentation via Investor Meet
Company.
IXICO PLC is pleased to announce that Giulio Cerroni (CEO),
Grant Nash (CFO) and Robin Wolz (CSO) will provide a live
presentation relating to the half-year results of the Company via
the Investor Meet Company platform on 23rd May 2023 at 4:30pm BST.
The presentation is open to all existing and potential
shareholders.
Questions can be submitted pre-event via your Investor Meet
Company dashboard up until 9am the day before the meeting or at any
time during the live presentation.
Investors can sign up to Investor Meet Company for free and add
to meet IXICO PLC via:
https://www.investormeetcompany.com/ixico-plc/register-investor
.
Investors who already follow IXICO PLC on the Investor Meet
Company platform will automatically be invited.
For further information please contact:
IXICO plc +44 (0)20 3763 7499
Giulio Cerroni, Chief Executive
Officer
Grant Nash, Chief Financial Officer
Cenkos Securities PLC (Nominated adviser
and sole broker) +44 (0)20 7397 8900
Giles Balleny / Max Gould (Corporate
Finance)
Michael F Johnson / Tamar Cranford-Smith
(Sales)
About IXICO | Advanced Analytics | Intelligent Insights.
IXICO is dedicated to delivering insights in neuroscience to
help transform the advancement of investigational therapies for
neurological diseases, such as Huntington's, Parkinson's,
Alzheimer's disease and Multiple Sclerosis. The Company's purpose
is to advance medicine and human health by turning data into
clinically meaningful information, providing valuable new insights
in neuroscience by supporting pharmaceutical companies across all
phases of CNS clinical research. IXICO's goal is to be a leading
advocate of artificial intelligence in medical image analysis.
IXICO has developed and deployed breakthrough machine learning
Ai data analytics, at scale, through its remote access TrialTracker
technology platform, to improve the return on investment in drug
development and reduce risk and uncertainty in clinical trials for
the Company's pharmaceutical clients.
More information is available on www.IXICO.com and follow us on
Twitter @IXICOnews
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRASFFFMIEDSEDI
(END) Dow Jones Newswires
May 16, 2023 02:00 ET (06:00 GMT)
Ixico (LSE:IXI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Ixico (LSE:IXI)
Historical Stock Chart
From Apr 2023 to Apr 2024